Immunotherapy Boosts Survival in Some Endometrial Cancers

A real-world US study links the combined treatment to longer survival only in mismatch repair-deficient disease.

Updated on Nov. 19, 2026 in Cancer

Immunotherapy Boosts Survival in Some Endometrial Cancers

A US real-world study found that adding immunotherapy to chemotherapy improved progression-free and overall survival in mismatch repair-deficient (dMMR) endometrial cancer. The study found no statistically significant benefit in mismatch repair-proficient (pMMR) disease.

Why it matters

The findings suggest that tumor mismatch repair status may help identify which endometrial cancer patients benefit from immunotherapy plus chemotherapy. Because the analysis is retrospective and observational, researchers say prospective investigation is needed before treatment guidelines change.

The analysis compared 290 patients receiving immunotherapy plus chemotherapy against 787 receiving carboplatin and paclitaxel alone, in a retrospective observational design. Whether these associations would be confirmed in prospective trials remains unknown.

The players

Dr. Christian Marth

Dr. Christian Marth is a physician who discussed the study findings and called for prospective investigation before guidelines change.

The details

Presented at the IGCS 2026 Annual Global Meeting, the study grouped patients by whether they received immunotherapy plus chemotherapy or carboplatin and paclitaxel alone. Dr. Christian Marth discussed the findings and called for prospective investigation before guidelines change.

Timeline

  1. 2026: The study was presented at the IGCS 2026 Annual Global Meeting.

Treatment Landscape

Mismatch repair deficiency testing has increasingly been used to classify endometrial tumors, and this real-world analysis links that classification to differing responses to immunotherapy plus chemotherapy. The results add US real-world evidence to that classification approach, though guideline changes await prospective confirmation.

For patients with endometrial cancer, tumor mismatch repair testing may become more relevant to treatment discussions with their doctors. Any change in standard treatment would depend on prospective trials and updated clinical guidelines.

The takeaway

Patients and clinicians should watch for prospective trials that test whether mismatch repair status should guide immunotherapy use in endometrial cancer. Until then, these real-world findings are best treated as hypothesis-generating rather than practice-changing.

Further reading

Explore more cancer research and treatment coverage on Wisevoter.

Source note: This article includes information reported by OncLive.